Home/Filings/4/0001437749-20-013678
4//SEC Filing

Wong Vivien 4

Accession 0001437749-20-013678

CIK 0000835887other

Filed

Jun 22, 8:00 PM ET

Accepted

Jun 23, 4:48 PM ET

Size

32.4 KB

Accession

0001437749-20-013678

Insider Transaction Report

Form 4
Period: 2020-06-19
Wong Vivien
Executive Vice President
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-06-1982,5000 total
    Exercise: $4.52Exp: 2026-02-28Common Stock (82,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-06-1975,0000 total
    Exercise: $4.70Exp: 2024-03-02Common Stock (75,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-06-1994,8750 total
    Exercise: $6.62Exp: 2028-02-29Common Stock (94,875 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-06-1940,0000 total
    Exercise: $9.81Exp: 2022-02-28Common Stock (40,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-06-1952,8000 total
    Exercise: $4.70Exp: 2024-03-02Common Stock (52,800 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-06-1982,5000 total
    Exercise: $11.32Exp: 2027-02-28Common Stock (82,500 underlying)
  • Disposition to Issuer

    Common Stock

    2020-06-194,1210 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-06-196,0000 total
    Exercise: $5.35Exp: 2020-06-30Common Stock (6,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-06-1925,0000 total
    Exercise: $4.83Exp: 2020-10-31Common Stock (25,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-06-1960,0000 total
    Exercise: $7.40Exp: 2021-06-30Common Stock (60,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-06-1948,0000 total
    Exercise: $5.03Exp: 2023-04-03Common Stock (48,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-06-1966,0000 total
    Exercise: $6.65Exp: 2025-03-01Common Stock (66,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-06-1990,7500 total
    Exercise: $4.52Exp: 2029-03-01Common Stock (90,750 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2020-06-1982,2140 total
    Exercise: $4.77Exp: 2030-03-02Common Stock (82,214 underlying)
Footnotes (6)
  • [F1]On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. Pursuant to the Merger Agreement, each share of Progenics common stock was cancelled and converted into the right to receive (i) 0.31 of a share of Lantheus common stock (with such fraction of a Lantheus share having a market value of $4.60 on the effective date of the Merger) and (ii) one contingent value right (a "CVR") issued by Lantheus subject to and in accordance with the Contingent Value Rights Agreement, dated June 19, 2020, between Lantheus and Computershare Trust Company, N.A.
  • [F2]Each of these options is fully vested and exercisable.
  • [F3]At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the current vesting and other terms of the option continue in effect.
  • [F4]This option is scheduled to vest in annual installments over the three-year period commencing March 1, 2018.
  • [F5]This option is scheduled to vest in annual installments over the three-year period commencing March 1, 2019.
  • [F6]This option is scheduled to vest in annual installments over the three-year period commencing March 2, 2020.

Issuer

PROGENICS PHARMACEUTICALS INC

CIK 0000835887

Entity typeother

Related Parties

1
  • filerCIK 0001638050

Filing Metadata

Form type
4
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 4:48 PM ET
Size
32.4 KB